Hunan Hansen Pharmaceutical Co., Ltd. 2026 First Quarter Report Securities Code: 002412 Securities Abbreviation: Hansen Pharmaceutical Announcement Number: 2026-009
Hunan Hansen Pharmaceutical Co., Ltd. 2026 First Quarter Report
The Company and its entire Board of Directors guarantee the content of this information disclosure is true, accurate, and complete, with no false records, misleading statements, or major omissions.
Important Content Notice:
- The Board of Directors and its members, senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report, with no false records, misleading statements, or major omissions, and shall bear individual and joint legal liabilities.
- The Company's principal, head of accounting and head of the accounting department (accounting supervisor) declare: guarantee the truthfulness, accuracy, and completeness of the financial information in the quarterly report.
- Has the first quarter financial report been audited? No
I. Main Financial Data (I) Main Financial Data and Indicators Does the company need to retrospectively adjust or restate previous year's accounting data? No
Unit: RMB Reporting Period Previous Year Period Year-on-Year Change (%) Operating Revenue (RMB) 263, 228, 412.01 269, 286, 565.75 -2.25% Net Profit Attributable to Shareholders of Listed Companies (RMB) 38, 406, 422.88 11, 257, 164.35 241.17% Net Profit Attributable to Shareholders of Listed Companies After Deducting Non-Recurring Gains and Losses (RMB) 36, 085, 207.02 9, 116, 396.99 295.83% Net Cash Flow from Operating Activities (RMB) -10, 422, 794.53 49, 407, 081.75 -121.10% Basic Earnings Per Share (RMB/Share) 0.0763 0.0224 240.63% Diluted Earnings Per Share (RMB/Share) 0.0763 0.0224 240.63% Weighted Average Return on Equity 1.60% 0.51% 1.09%